SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Mosapride citrate dihydrate

Cat. No.:	HY-B0189B
CAS No.:	636582-62-2
Molecular Formula:	$C_{27}H_{37}ClFN_3O_{12}$
Molecular Weight:	650.05
Target:	5-HT Receptor; Potassium Channel; Cytochrome P450
Pathway:	GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



BIOLOGICAL ACTIVITY

Description	Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine$_4$ receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC_{50} values of 15.2 μM[1]. Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo[2].	
IC_{50} & Target	5-HT_4 Receptor	Kv4.3 15.2 μM (IC_{50})
In Vitro	Mosapride (0.3-30 μM) exhibits an inhibitory activity against Kv4.3 with an IC_{50} of 15.2 μM in a concentration-dependent manner. Mosapride also inhibits the open state of Kv4.3 currents during depolarization and accelerates the closed-state inactivation at subthreshold potentials[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Mosapride (Intravenous injection;0.3-3 mg/kg) dose-dependently increases the antral motor activity in conscious dogs which indicates that mosapride selectively stimulates upper gastrointestinal motility[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

Animal Model:	Beagle dogs[2]
Dosage:	0.3-3 mg/kg
Administration:	Intravenous injection; 0.3-3 mg/kg
Result:	Increased the antral motor activity dose-dependently in conscious dogs.

CUSTOMER VALIDATION

- J Ethnopharmacol. 2024 Apr 15:329:118118.
- J Appl Microbiol. 2023 Jul 22;lxad153.

- Chin J Integr Med. 2022 Aug 31.
- Drug Metab Pharmacokinet. 2020 Feb;35(1):102-110.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013;386(10):905-16.

[2]. Mine Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. The Journal of pharmacology and experimental therapeutics. 1997;283(3):1000-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA